RxGenomix and Translational Software (TSI), a leader in the intelligent use of genetic data for clinical decision support and precision medicine, have formed a partnership that increases the value of our individual offerings and makes it easier for a wide range of employers, payors, and healthcare providers to implement pharmacogenomics as a compelling component of their clinical and benefits strategies.

Together, our combined solution of claims analytics, clinical decision support, extensive provider education and a pharmacist-led program offering seeks to make PGx more accessible and more effective in improving clinical outcomes while reducing overall healthcare costs. 

“After surveying the market,  we found Translational Software (TSI) to have strict evidence-based standards for all of its guidance, and a track record of complex PGx deployments across different stakeholders that complements our continued strategy of pharmacist-led PGx capabilities,” said RxGenomix COO Blake Keller, PharmD. “TSI also brings the right security posture, and a flexible and collaborative partnership approach which accelerates RxGenomix’s ability to deploy the most comprehensive and effective PGx offering in healthcare.”